Factors predicting achievement of recommend time-in-range at 6-months postcommencement amongst closed-loop users with elevated baseline HbA1c levels.
Authors:
TSJ Crabtree, TP Griffin, P Narendran, G Gallen, J Elliott, YW Yap, A Lumb, P Hammond, REJ Ryder, P Choudhary, EG Wilmot on behalf of all ABCD Closed-Loop Audit contributors.
Changes in HbA1c and sensor glucometrics 6-months following HCL commencement in individuals with HbA1c³86mmol/mol: Sub-analysis from the ABCD Closed-Loop audit of the NHS England Pilot.
Authors:
TSJ Crabtree TP Griffin, P Narendran, MA Karamat, G Gallen, J Elliott, Z Bawlchhim, A Chapman, A Lumb, P Hammond, REJ Ryder, P Choudhary, EG Wilmot on behalf of all ABCD Closed-Loop Audit contributors.
Who is using the OmniPod® DASH in the Association of British Clinical Diabetologists (ABCD) Audit: An interim report of baseline characteristics.
Authors:
TSJ Crabtree, M Haq, E Gatdula, N Hassan, J Varghese, K Bull, A Lumb, L Leelarathna, P Narendran, S Hussain, F Gibb, P Hammond, P Choudhary, EG Wilmot on behalf of all ABCD Worldwide Omnipod Audit contributors.
Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide.
Authors:
In January 2023 the decision to discontinue the remaining presentations of Insuman® regular human, isophane and isophane pre-mixed insulins in the UK, phased over the following 6 months, was announced.
Unfortunately, due to unexpected capacity and component part constraints at plant, Sanofi is expected to discontinue the following products by the end of February 2023:
Endoscopic proximal intestinal exclusion can improve non-alcoholic fatty liver disease (NAFLD) in patients with diabesity
Authors
Hayee B, Sen Gupta P, Anderson M , Fogden E , Roy AA , Butler DB , Bajwa RS , Amiel SA , Ryder REJ
One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion using Endobarrier as an Adjunct to Glucagon-like Peptide-1 (GLP-1) therapy in Suboptimally Controlled Type 2 Diabetes: a Randomised Controlled Trial
Authors
E Fogden*, P Sen Gupta, M Anderson, B Hayee, RS Drummond, BM McGowan, SA Amiel, REJ Ryder
One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion Using Endobarrier as an Adjunct to Glucagon-like Peptide-1 (GLP-1) Therapy in Suboptimally Controlled Type 2 Diabetes: A Randomised Controlled Trial
Presenting Author Piya Sen Gupta City Hospital
Author Russell S Drummond Glasgow Royal Infirmary
Author Barbara MC McGowan Guys and St Thomas' hospital
Author Stephanie A Amiel King's College London
Author Robert EJ Ryder City Hospital
Author Sebastian T Lugg City Hospital
